2-(4-Methylphenoxy)-6-methylpyridin | 28370-04-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-Methylphenoxy)-6-methylpyridin
• 英文别名: 2-Methyl-6-(4-methylphenoxy)pyridine
• CAS: 28370-04-9
• 化学式: C₁₃H₁₃NO
• 分子量: 199.252
• InChiKey: XQGSWGAVXZEIPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] FGFR INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE FGFR ET LEURS PROCÉDÉS D'UTILISATION
  申请人：RELAY THERAPEUTICS INC

  公开号：WO2020231990A1

  公开（公告）日：2020-11-19

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.

  本公开涉及新化合物及其药物组合物，以及使用该公开的化合物和组合物抑制FGFR酶活性的方法。本公开还涉及但不限于使用该公开的化合物和组合物治疗与FGFR信号传导相关的疾病的方法。
• GLYCINE B ANTAGONIST
  申请人：Henrich Markus

  公开号：US20110190342A1

  公开（公告）日：2011-08-04

  The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

  本发明涉及喹啉衍生物及其药学上可接受的盐。本发明还涉及制备这种化合物的过程。本发明的化合物是甘氨酸B拮抗剂，因此对控制和预防各种疾病，包括神经系统疾病，非常有用。
• 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20140315903A1

  公开（公告）日：2014-10-23

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
• US4661501A
  申请人：——

  公开号：US4661501A

  公开（公告）日：1987-04-28
• US4814340A
  申请人：——

  公开号：US4814340A

  公开（公告）日：1989-03-21